Document Detail


Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma.
MedLine Citation:
PMID:  8063620     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the delivery of adriamycin (ADR) to the regional lymph nodes of the stomach following the gastric submucosal injection of liposomal adriamycin (Lipo-ADR) in 34 gastric carcinoma patients, as well as following intravenous administration of free ADR (F-ADR) in another 18 patients. Prior to radical gastrectomy, Lipo-ADR was endoscopically injected into the gastric submucosa adjacent to the primary tumor via a needle-tipped catheter. After Lipo-ADR injection, the ADR concentration in the primary and secondary drainage lymph nodes was higher than in the other regional lymph nodes. Thus, the regional nodes more susceptible to metastasis showed higher levels of ADR. In contrast, the intravenous administration of F-ADR produced a similar and far lower ADR concentration in all the nodes. Delivery of ADR to the primary drainage lymph nodes following injection of 5 ml of Lipo-ADR was compared with delivery to the left gastric artery lymph nodes after intravenous administration of an equal dose of F-ADR. The ADR levels (micrograms/g) after gastric submucosal injection were 15.1 +/- 8.30 on day 1 (n = 4); and 11.9 +/- 4.80 on day 4 (n = 6). Those after intravenous administration were 0.29 +/- 0.10 on day 1 (n = 4); and 0.36 +/- 0.0 on day 4 (n = 2). The differences between the two groups were significant (P < 0.05). The ADR levels after the gastric submucosal injection were far higher than those after intravenous administration. These findings indicate that the gastric submucosal injection of Lipo-ADR can specifically deliver ADR to the regional lymph nodes at high concentrations. Such preoperative adjuvant chemotherapy targeting the regional lymph nodes may be useful for preventing the lymph node recurrence of gastric carcinoma.
Authors:
Y Akamo; I Mizuno; T Yotsuyanagi; T Ichino; N Tanimoto; T Yamamoto; M Nagata; H Takeyama; N Shinagawa; J Yura
Publication Detail:
Type:  Case Reports; Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Japanese journal of cancer research : Gann     Volume:  85     ISSN:  0910-5050     ISO Abbreviation:  Jpn. J. Cancer Res.     Publication Date:  1994 Jun 
Date Detail:
Created Date:  1994-09-21     Completed Date:  1994-09-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8509412     Medline TA:  Jpn J Cancer Res     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  652-8     Citation Subset:  IM    
Affiliation:
First Department of Surgery, Nagoya City University Medical School.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant
Combined Modality Therapy
Doxorubicin / administration & dosage*,  adverse effects,  pharmacokinetics
Drug Administration Routes
Drug Carriers
Female
Gastrectomy
Gastric Mucosa
Humans
Injections, Intravenous
Liposomes
Lymph Nodes / metabolism*
Lymphatic Metastasis
Male
Middle Aged
Preoperative Care
Stomach Neoplasms / drug therapy*,  surgery
Chemical
Reg. No./Substance:
0/Drug Carriers; 0/Liposomes; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the...
Next Document:  Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluoroura...